Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with we ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower ... related to the gastrointestinal system -- for example, nausea, constipation, diarrhea or belching.

One such example is SGLT2 inhibitors like Farxiga (dapagliflozin), Jardiance (empagliflozin), and Invokana (canagliflozin). These can aid in weight loss, lower the risk of cardiovascular disease, and ...

Here are five questions answered about the FDA's decision to halt compounded versions of GLP-1 drugs. The FDA says state-licensed compounding pharmacies must immediately stop making most compound ...